Proof-of-Concept Studies to Support the Use of
the Hemopurifier in the Ex Vivo Organ Perfusion
Circuit
SAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical therapeutic company focused on
developing products to treat cancer and life-threatening infectious
diseases, today announced that it has signed a Collaboration
Agreement with 34 Lives, PBC, to investigate the use of Aethlon's
proprietary Hemopurifier® technology and 34 Lives' organ
evaluation and preservation system, with the goal of increasing the
supply of useable donated kidneys for human transplant. Financial
terms of the agreement were not disclosed.
"The signing of the research collaboration with 34 Lives, on the
heels of our recent announcement of our interest in the organ
transplant market, is a testament to Aethlon's belief that the
Hemopurifier technology can potentially help expand the pool for
donated kidneys available for transplant," stated Charles J. Fisher, Jr., M.D., Chief Executive
Officer of Aethlon Medical. "The aim of the proof-of-concept
studies, to be conducted under this Agreement, is to gather
compelling data to support the use of our technology in the ex vivo
organ preservation system and to confirm its ability to remove
harmful viruses and exosomes with injurious cargo from recovered
donor organs. Aethlon has previously demonstrated the removal of
multiple viruses and exosomes in vitro, utilizing a miniature
version of the Hemopurifier. This process may reduce complications
following transplantation of the recovered organ, including viral
infection, delayed graft function and rejection by the transplant
recipient. We look forward to working with 34 Lives with the goal
of preserving the viability of kidneys, with the ultimate goal of
saving lives." Chris Jaynes, Chief
Executive Officer of 34 Lives added, "The combination of the
Aethlon Hemopurifier with the 34 Lives' organ preservation system
may also help rescue a large percentage of the donor kidneys
annually recovered for transplantation that go unused, putting them
back into the donor pool with the hope of eliminating the patient
waitlist for these organs."
According to Precedence Research, the global transplantation
market size is projected to hit around $33.7
billion by 2032, up from an estimated $15.1 billion in 2022, driven largely by
increasing rates of organ failure and demand for novel tissue
transplantation products. Additionally, according to 34 Lives, in
2022, approximately 115,000 patients in the U.S. were awaiting
organ transplants. Of these, 96,000 were waiting for a kidney,
facing an average wait time of six years, while more than 7,800
kidneys which were recovered for transplant, were left unused.
About 34 Lives, PBC
34 Lives is a Public Benefit Corporation, which is a company
that prioritizes societal benefits over profits. 34 Lives is
committed to saving and dramatically improving the lives of more
than 120,000 individuals waiting for lifesaving organ transplants,
84% of whom are waiting for kidneys. 34 Lives' innovative processes
and services are intended to extend the safe preservation times to
the thousands of unused kidneys each year, saving lives that would
otherwise be lost on the waitlist.
About Aethlon and the
Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful
exosomes from blood utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where
exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to
successfully complete development of the Hemopurifier and to
successfully demonstrate the utility of the Hemopurifier in the
organ transplant field in collaboration with 34 Lives, the
Company's ability to manage its clinical trials, and other
potential risks. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could
cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended March 31, 2023, and in the
Company's other filings with the Securities and Exchange
Commission, including its quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-signs-collaboration-agreement-with-34-lives-to-evaluate-the-ability-of-the-hemopurifier-to-expand-the-utility-of-unused-donated-kidneys-for-transplant-301882726.html
SOURCE Aethlon Medical, Inc.